CN115427075A - 抗hepsin抗体及其用途 - Google Patents

抗hepsin抗体及其用途 Download PDF

Info

Publication number
CN115427075A
CN115427075A CN202180026877.6A CN202180026877A CN115427075A CN 115427075 A CN115427075 A CN 115427075A CN 202180026877 A CN202180026877 A CN 202180026877A CN 115427075 A CN115427075 A CN 115427075A
Authority
CN
China
Prior art keywords
cdr
antibody
seq
hepsin
numbering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180026877.6A
Other languages
English (en)
Chinese (zh)
Inventor
布莱克·P·约翰逊
蒂莫西·J·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navax
Original Assignee
Navax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navax filed Critical Navax
Publication of CN115427075A publication Critical patent/CN115427075A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
    • G01N2470/04—Sandwich assay format

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180026877.6A 2020-02-05 2021-02-03 抗hepsin抗体及其用途 Pending CN115427075A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970626P 2020-02-05 2020-02-05
US62/970,626 2020-02-05
PCT/US2021/016409 WO2021158660A2 (en) 2020-02-05 2021-02-03 Anti-hepsin antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115427075A true CN115427075A (zh) 2022-12-02

Family

ID=77200525

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026877.6A Pending CN115427075A (zh) 2020-02-05 2021-02-03 抗hepsin抗体及其用途

Country Status (11)

Country Link
US (1) US20230236192A1 (https=)
EP (1) EP4100062A4 (https=)
JP (1) JP2023512782A (https=)
KR (1) KR20220137696A (https=)
CN (1) CN115427075A (https=)
AU (1) AU2021215999A1 (https=)
BR (1) BR112022015523A2 (https=)
CA (1) CA3169809A1 (https=)
IL (1) IL295258A (https=)
MX (1) MX2022009584A (https=)
WO (1) WO2021158660A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259819A1 (en) * 2024-06-11 2025-12-18 Navaux, Inc. Anti-hepsin antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
WO2011161189A1 (en) * 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CN102648211A (zh) * 2009-10-22 2012-08-22 霍夫曼-拉罗奇有限公司 抗hepsin抗体及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524605A (ja) * 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US8383351B2 (en) * 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
WO2010082034A1 (en) * 2009-01-16 2010-07-22 University Of Exeter Antibody
CN102093479B (zh) * 2010-11-29 2012-10-03 侯宗柳 抗人血管内皮生长因子受体2的重组嵌合抗体
EP2721417A4 (en) * 2011-06-17 2015-05-06 Univ Arkansas NEW MARKERS FOR EARLY DIAGNOSIS OF EGG CANCER, MONITORING DURING THE CORRESPONDING THERAPY AND NEW THERAPY OPTIONS DURING AND AFTER THE CORRESPONDING CHEMOTHERAPY
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
CN102648211A (zh) * 2009-10-22 2012-08-22 霍夫曼-拉罗奇有限公司 抗hepsin抗体及其使用方法
WO2011161189A1 (en) * 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANAI XUAN等: "Antibodies Neutralizing Hepsin Protease Activity Do Not Impact Cell Growth but Inhibit Invasion of Prostate and Ovarian Tumor Cells in Culture", 《CANCER RES》, vol. 66, no. 7, 1 April 2006 (2006-04-01), pages 3611 - 3619, XP002461477, DOI: 10.1158/0008-5472.CAN-05-2983 *

Also Published As

Publication number Publication date
WO2021158660A2 (en) 2021-08-12
KR20220137696A (ko) 2022-10-12
BR112022015523A2 (pt) 2022-09-27
JP2023512782A (ja) 2023-03-29
EP4100062A2 (en) 2022-12-14
MX2022009584A (es) 2022-10-07
US20230236192A1 (en) 2023-07-27
AU2021215999A1 (en) 2022-09-01
CA3169809A1 (en) 2021-08-12
WO2021158660A3 (en) 2021-09-23
IL295258A (en) 2022-10-01
EP4100062A4 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
JP7455787B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
AU2018277838B2 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
CN112533955B (zh) 抗b7-h3抗体
CN102844332B (zh) 呈pH依赖性抗原结合的抗体
CN102333542B (zh) Pcsk9拮抗剂
CN107530429A (zh) 特异性针对糖基化的pd‑l1的抗体及其使用方法
CA2984945A1 (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
US20230146072A1 (en) Anti-gucy2c antibodies and uses thereof
CN110382532A (zh) 抗g-csf抗体及其用途
JP2016523235A (ja) 補体因子ｈ阻害薬
CN114470194A (zh) 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
WO2022026775A1 (en) Compositions and methods for targeting coronavirus
CN114729045B (zh) 对糖基化的ctla-4特异性的抗体及其使用方法
US20230236192A1 (en) Anti-hepsin antibodies and uses thereof
US20250270346A1 (en) Efficacious anti-cd26 antibody biomarker
CN116940595A (zh) 抗tigit抗体及其用途
CN114761042A (zh) Il-38特异性抗体
CN121319180A (zh) 靶向PD-L1和TGF-β的双功能分子
CN113597432A (zh) 抗EpCAM抗体及其应用
CN114829404B (zh) 对糖基化的lag3特异的抗体及其使用方法
TW202302635A (zh) Ｉｌ－３８專一性抗體
CN121443642A (zh) 抗ror1抗体及其用途
HK1208688A1 (zh) 基质金属蛋白酶9的抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20221202

RJ01 Rejection of invention patent application after publication